Epoetin beta
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | B03XA01 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
ChemSpider | none |
UNII | 64FS3BFH5W |
(what is this?) (verify) |
Epoetin beta (rINN) /ɛˈpoʊ.ᵻtᵻn/ is a synthetic, recombinant[1] form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Epoetin is marketed under the trade names NeoRecormon.[2]
References
- ↑ Dunn CJ, Markham A (1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs. 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169.
- ↑ Amgen - Products. URL: http://www.amgen.com/patients/prca.html. Accessed on: October 21, 2007.
External links
- Jenkins, John K. (2007-06-26). "Congressional Testimony: Erythropoiesis-Stimulating Agents (ESA)". News & Events. FDA. Retrieved 2010-02-25.
This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.